|Source: 2Q12 10Q filing (p. 14). Click to enlarge.|
The company, in my view, has received an SPA for its pivotal MM Phase 3 trial, the top-line parameters of which, were presented in Munich at the end of June.
We await the PR for this, whether that PR is issued before the end of the month or shortly after Labor Day.
I will delve into the SPA topic and others (highlighted above) in subsequent blog posts, presenting my analyses that supports my conclusions, over the next few days.